POLIO
MCID: PLM031
MIFTS: 57

Poliomyelitis (POLIO)

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 74 52 58 43 15 17 71
Infantile Paralysis 52 71
Polio 52 54

Characteristics:

Orphanet epidemiological data:

58
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD9CM 34 045 045.9
MeSH 43 D011051
NCIt 49 C35550
SNOMED-CT 67 54839009
ICD10 32 A80 A80.9
MESH via Orphanet 44 D011051
ICD10 via Orphanet 33 A80.0 A80.1 A80.2 more
UMLS via Orphanet 72 C0032371
Orphanet 58 ORPHA2912
UMLS 71 C0032371 C1527258

Summaries for Poliomyelitis

NIH Rare Diseases : 52 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis . It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and diphtheria. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Polymyxin B and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and spinal cord, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 74 Polio, short for poliomyelitis, or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 710)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 33.7 RASA3 PVR KHSRP EVC BTK ARHGEF1
2 diphtheria 31.7 TNF IL4 IFNG CD40LG
3 tetanus 31.5 TNF IL4 IL10 IFNG CD40LG
4 smallpox 31.3 TNF IL4 IFNG ICAM1
5 myelitis 31.1 TNF IL10 CD40LG
6 aseptic meningitis 31.1 TNF IL10 IFNG CD40LG
7 mumps 31.1 TNF IL10 IFNG CD40LG
8 neuritis 31.1 TNF IL4 IL10 IFNG
9 rubella 30.9 TNF IL4 IL10 IFNG CD40LG
10 hand, foot and mouth disease 30.8 SCARB2 IL10 IFNG
11 meningoencephalitis 30.7 TNF IL10 CD40LG
12 viral encephalitis 30.7 TNF IL10 CD40LG
13 dermatitis 30.7 TNF IL4 IL10 IFNG
14 graft-versus-host disease 30.6 TNF IL10 IFNG
15 sleep apnea 30.6 TNF LEP IL10 ICAM1
16 acute hemorrhagic conjunctivitis 30.6 ICAM1 EVC CD40LG
17 myasthenia gravis 30.6 TNF IL4 IL10 IFNG
18 myocarditis 30.6 TNF IL4 IL10 IFNG ICAM1 CD40LG
19 penicillin allergy 30.6 IL4 IL10 IFNG
20 hepatitis a 30.6 TNF IL4 IL10 IFNG
21 osteomyelitis 30.5 TNF IL4 IL10 IFNG
22 arthritis 30.5 TNF IL4 IL10 IFNG ICAM1
23 multiple sclerosis 30.5 TNF IL4 IL10 IFNG ICAM1 CD40LG
24 typhoid fever 30.5 TNF IFNG CD40LG
25 exanthem 30.5 TNF IL10 CD40LG
26 combined t cell and b cell immunodeficiency 30.5 IL4 IL10 CD40LG
27 spondylitis 30.5 TNF IL10 IFNG
28 chickenpox 30.5 TNF IL4 IL10 IFNG CD40LG
29 bacterial meningitis 30.4 TNF IL10 IFNG
30 conjunctivitis 30.4 TNF IL4 IL10 IFNG ICAM1 BTK
31 chronic fatigue syndrome 30.4 TNF IL4 IL10 IFNG
32 pulmonary edema 30.4 TNF IL10 ICAM1
33 diarrhea 30.3 TNF IL10 IFNG CD40LG
34 meningitis 30.3 TNF IL4 IL10 IFNG ICAM1 FCGR2A
35 mycobacterium tuberculosis 1 30.3 TNF IL4 IL10 IFNG
36 pyelonephritis 30.3 TNF IL10 IFNG
37 appendicitis 30.3 TNF IL10 IFNG
38 arteriosclerosis 30.3 IL4 IL10 IFNG ICAM1
39 reactive arthritis 30.3 TNF IL10 IFNG
40 agammaglobulinemia, x-linked 30.3 IL4 CD40LG BTK
41 acquired immunodeficiency syndrome 30.2 TNF IL10 IFNG ICAM1 FCGR3A CD40LG
42 chlamydia pneumonia 30.2 TNF IL10 CD40LG
43 immune deficiency disease 30.2 TNF IL4 IL10 IFNG CD40LG BTK
44 trichinosis 30.2 IL4 IL10 CD40LG
45 thrombocytopenia due to platelet alloimmunization 30.2 IL10 FCGR2A CD40LG
46 allergic hypersensitivity disease 30.2 TNF IL4 IL10 IFNG ICAM1
47 common cold 30.2 TNF IL4 IL10 ICAM1
48 neuromuscular disease 30.2 TNF PES1 IL10 CD40LG
49 neuromuscular junction disease 30.2 IL4 IL10 CD40LG
50 tonsillitis 30.2 TNF IL4 IL10 IFNG

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

MGI Mouse Phenotypes related to Poliomyelitis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 BTK CD40LG DLG1 EVC ICAM1 IFNG
2 hematopoietic system MP:0005397 10.21 ARHGEF1 BTK CD40LG DLG1 FCGR2A FCGR3B
3 cardiovascular system MP:0005385 10.19 ARHGEF1 CD40LG ICAM1 IFNG IL10 KCNJ12
4 growth/size/body region MP:0005378 10.18 BTK DLG1 EVC ICAM1 IFNG IL10
5 homeostasis/metabolism MP:0005376 10.17 ARHGEF1 BTK CD40LG DLG1 FCGR3B ICAM1
6 immune system MP:0005387 10.13 ARHGEF1 BTK CD40LG DLG1 FCGR2A FCGR3B
7 digestive/alimentary MP:0005381 10.03 BTK DLG1 ICAM1 IFNG IL10 IL4
8 craniofacial MP:0005382 10 DLG1 EVC IFNG IL10 IL4 PES1
9 mortality/aging MP:0010768 9.86 ARHGEF1 BTK CD40LG DLG1 EVC FCGR2A
10 integument MP:0010771 9.81 BTK CD40LG ICAM1 IFNG IL10 IL4
11 skeleton MP:0005390 9.36 CD40LG DLG1 EVC FCGR2A FCGR3B IFNG

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Calcium carbonate Approved, Investigational Phase 4 471-34-1
5
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
6
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
7
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
8
Pentetic acid Approved Phase 4 67-43-6
9
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
11
BCG vaccine Investigational Phase 4
12 Antibodies, Blocking Phase 4
13 Polymyxins Phase 4
14 Protective Agents Phase 4
15 Antioxidants Phase 4
16 Nutrients Phase 4
17 Trace Elements Phase 4
18 Micronutrients Phase 4
19 Acidophilus Phase 4
20 Zinc Supplement Phase 4
21 Fibrinolytic Agents Phase 4
22 Anticoagulants Phase 4
23 Hormone Antagonists Phase 4
24 Melanocyte-Stimulating Hormones Phase 4
25 Adrenocorticotropic Hormone Phase 4
26 beta-endorphin Phase 4
27 Hormones Phase 4
28 Immunoglobulin A Phase 4
29 Vitamins Phase 4
30 retinol Phase 4
31 Retinol palmitate Phase 4
32 Chelating Agents Phase 4
33 Iron Chelating Agents Phase 4
34 Antidotes Phase 4
35 Vaccines Phase 4
36 Antibodies Phase 4
37 Immunoglobulins Phase 4
38 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
39 Chrysanthemum Phase 4
40
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3 58-14-0 4993
41
Sulfadoxine Approved, Investigational Phase 2, Phase 3 2447-57-6 17134
42
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
43
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955
44
Proguanil Approved Phase 2, Phase 3 500-92-5 4923
45
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
46
leucovorin Approved Phase 3 58-05-9 6006 143
47
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
48
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
49
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
50
Etoposide Approved Phase 3 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 330)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
2 Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study Completed NCT01244464 Phase 4
3 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
4 Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study Completed NCT01278433 Phase 4
5 Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone. Completed NCT01475539 Phase 4
6 Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
7 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
8 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
9 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic Completed NCT02580201 Phase 4
10 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
11 Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh Completed NCT02643368 Phase 4
12 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
13 A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs) Completed NCT01831050 Phase 4
14 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
15 Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants Completed NCT01616693 Phase 4
16 Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants. Completed NCT01695798 Phase 4
17 Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh Completed NCT02412514 Phase 4
18 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
19 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants Completed NCT02521974 Phase 4
20 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
21 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
22 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
23 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
24 Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines Completed NCT02847026 Phase 4
25 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
26 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
27 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
28 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
29 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
30 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
31 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
32 Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
33 Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age Completed NCT01457547 Phase 4
34 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
35 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
36 Assessment of the Immunogenicity of Three Doses of Bivalent, Trivalent or Type One Monovalent Oral Poliovirus Vaccines Provided at 2 or 4 Week Intervals Completed NCT01633216 Phase 4
37 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
38 Immunogenicity and Safety Profile of Primary Dose of Bivalent OPV (bOPV Bio Farma) Given Simultaneously With Pentabio® And Inactivated Poliovirus Vaccine (IPV) at the 4th Visit in Indonesian Infants Completed NCT03310073 Phase 4
39 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
40 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
41 A Randomized, Multi-center, Controlled Clinical Trial for Evaluating the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV Completed NCT04054492 Phase 4
42 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
43 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
44 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
45 Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study Completed NCT02542462 Phase 4 Rotarix®,;Rotarix®, with other routine vaccines;RotaTeq®,;RotaTeq®, with other routine vaccines
46 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
47 Assessment of the Effectiveness of Seasonal Trivalent Influenza Vaccine Among Children in Senegal Completed NCT00893906 Phase 4
48 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
49 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
50 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

40
Testes, Bone, Spinal Cord, Brain, Lung, Kidney, Heart

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 20207)
# Title Authors PMID Year
1
Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. 54 61
19457934 2009
2
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. 54 61
18317803 2008
3
Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. 54 61
17517601 2007
4
Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. 54 61
16336935 2005
5
A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. 54 61
15033568 2004
6
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. 54 61
14654644 2003
7
Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. 54 61
12970433 2003
8
Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. 54 61
14563307 2003
9
The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis. 54 61
12220986 2002
10
Recent insights into poliovirus pathogenesis. 54 61
11597452 2001
11
Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. 54 61
10777530 2000
12
Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. 54 61
9188553 1997
13
Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. 54 61
9203668 1997
14
Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. 54 61
2030351 1991
15
Identification of two determinants that attenuate vaccine-related type 2 poliovirus. 54 61
1847458 1991
16
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. 54 61
2170026 1990
17
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
18
Typing of Human Cosaviruses by sequencing of full VP1: Update on global genetic diversity and identification of possible new genotypes circulating in Tunisia, North Africa. 61
31715246 2020
19
Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine. 61
31959422 2020
20
Sense of Coherence and the Association with Sociodemographics and Disability Related Factors in Persons with Late Effects of Polio. 61
31102303 2020
21
Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. 61
31765719 2020
22
Evaluation of Immunization Services for Children of Migrant Workers Along Thailand-Myanmar Border: Compliance with Global Vaccine Action Plan (2011-2020). 61
32033393 2020
23
Commentary: Why Has Uptake of Pneumococcal Vaccines for Children Been So Slow? The Perils of Undervaluation. 61
31725554 2020
24
Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. 61
30788503 2020
25
Test-Retest Reliability of the Reintegration to Normal Living Index (RNL-I) to Assess Perceived Participation in Adults With Late Effects of Polio. 61
30900809 2020
26
Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine. 61
32037225 2020
27
Why are vaccines against many human viral diseases still unavailable; an historic perspective? 61
31502669 2020
28
Monitoring of enterovirus diversity in wastewater by ultra-deep sequencing: An effective complementary tool for clinical enterovirus surveillance. 61
31710918 2020
29
Two centuries of immunisation in the UK (part 1). 61
31272966 2020
30
Genome-Wide Association Study of Cryptosporidiosis in Infants Implicates PRKCA. 61
32019797 2020
31
Sabin Strain Inactivated Polio Vaccine for the Polio Endgame. 61
30788498 2020
32
Extra time and penalties in the polio endgame. 61
31918002 2020
33
Projection of Costs of Polio Eradication Compared to Permanent Control. 61
31565733 2020
34
Why is polio still here? A perspective from Pakistan. 61
31981552 2020
35
Antibody response to vaccination after haematopoietic cell transplantation in children using a reduced dose schedule-A retrospective cohort study. 61
31617270 2020
36
Hepatitis B Birth Dose Effects on Childhood Immunization in the U.S. 61
31959321 2020
37
Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. 61
31682981 2020
38
Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data. 61
31791812 2020
39
How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers. 61
30024308 2020
40
Non-polio enteroviruses among healthy children in the Philippines. 61
32013921 2020
41
Assessment of in-country capacity to maintain communicable disease surveillance and response services after polio eradication-Somalia. 61
31753675 2020
42
Life satisfaction in persons with late effects of polio: a test-retest reliability study. 61
31944564 2020
43
Antibiotics against poliovirus carriage: an additional tool in the polio endgame? 61
31935566 2020
44
Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. 61
31960533 2020
45
Corrigendum to "Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study" [Vaccine 37 (2019) 4275-4280]. 61
31848050 2020
46
Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. 61
31703934 2020
47
Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. 61
31982261 2020
48
Oral health inequalities between differently abled and healthy school children in Bengaluru-A cross-sectional study. 61
31710118 2020
49
The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015. 61
31718899 2020
50
Maternal education and the multidimensionality of child health outcomes in India. 61
31112112 2020

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 TNF RASA3 PVR IL4 IL10 IFNG
2
Show member pathways
13.32 TNF RASA3 IL4 IL10 IFNG ICAM1
3
Show member pathways
12.83 TNF IL4 IL10 IFNG ICAM1 CD40LG
4
Show member pathways
12.62 TNF IL4 IL10 IFNG CD40LG BTK
5
Show member pathways
12.58 TNF IL4 IL10 IFNG DLG1 CD40LG
6
Show member pathways
12.49 TNF IL4 IFNG ICAM1 FCGR3B FCGR3A
7 12.46 TNF PVR IL4 IL10 IFNG CD40LG
8
Show member pathways
12.31 LEP IL4 IL10 IFNG
9
Show member pathways
12.29 TNF IL4 IFNG ICAM1
10 12.17 TNF IL10 IFNG FCGR3B FCGR3A FCGR2A
11 12.06 PVR ICAM1 FCGR3A CD40LG
12 11.97 TNF IL4 IL10 IFNG FCGR2A
13 11.96 TNF IL4 IL10 ICAM1
14 11.95 TNF IFNG FCGR3B FCGR3A FCGR2A BTK
15 11.9 TNF ICAM1 CD40LG BTK
16
Show member pathways
11.9 TNF IL4 IFNG FCGR3B FCGR3A FCGR2A
17 11.86 IL10 ICAM1 FCGR3B FCGR3A FCGR2A
18
Show member pathways
11.83 TNF IL4 IL10 IFNG FCGR3B FCGR3A
19 11.78 TNF IL4 IL10 IFNG
20 11.76 IL4 IFNG ICAM1
21
Show member pathways
11.75 TNF IL4 IFNG CD40LG
22 11.71 TNF LEP IL4 IFNG ICAM1 FCGR2A
23 11.7 TNF IL10 IFNG
24
Show member pathways
11.65 TNF IFNG ICAM1 CD40LG
25 11.63 IL4 IL10 CD40LG
26 11.52 TNF IL4 IL10 ICAM1
27 11.48 IL4 IL10 IFNG
28 11.36 TNF IL10 IFNG ICAM1
29 11.35 TNF IL10 IFNG ICAM1 CD40LG
30 11.32 IL4 IFNG CD40LG
31 11.3 TNF IL4 IFNG
32 11.22 TNF IL4 IL10 IFNG
33 11.19 IL4 IL10 IFNG
34 11.02 TNF IL4 IL10 IFNG FCGR3B FCGR3A
35 11.01 TNF IL4 IL10 CD40LG BTK ARHGEF1

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNF PVR LEP IL4 IL10 IFNG
2 membrane GO:0016020 9.86 TNF SCARB2 RASA3 PVR PES1 KHSRP
3 plasma membrane GO:0005886 9.47 TNF SCARB2 RASA3 PVR KCNJ12 ICAM1
4 membrane raft GO:0045121 9.46 TNF ICAM1 DLG1 BTK

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF ICAM1 CD40LG BTK
2 viral entry into host cell GO:0046718 9.82 SCARB2 PVR ICAM1
3 B cell differentiation GO:0030183 9.81 IL4 IL10 CD40LG
4 response to insulin GO:0032868 9.8 LEP IL10 ICAM1
5 regulation of insulin secretion GO:0050796 9.79 TNF LEP IFNG
6 positive regulation of T cell proliferation GO:0042102 9.77 LEP IL4 CD40LG
7 positive regulation of protein localization to plasma membrane GO:1903078 9.76 TNF IFNG DLG1
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.72 TNF IFNG ICAM1
9 negative regulation of mitotic cell cycle GO:0045930 9.67 TNF IL10 DLG1
10 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 TNF ICAM1
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 IL4 IL10 ICAM1
12 regulation of immune response GO:0050776 9.65 PVR IL4 ICAM1 FCGR3A CD40LG
13 positive regulation of chemokine biosynthetic process GO:0045080 9.64 TNF IFNG
14 negative regulation of amyloid-beta clearance GO:1900222 9.63 TNF IFNG
15 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.63 IL4 IL10
16 negative regulation of lipid storage GO:0010888 9.62 TNF LEP
17 endothelial cell apoptotic process GO:0072577 9.61 TNF IL10
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 TNF IL10
19 neuroinflammatory response GO:0150076 9.58 IL4 IFNG
20 positive regulation of JAK-STAT cascade GO:0046427 9.58 TNF LEP IL10
21 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
22 type 2 immune response GO:0042092 9.56 IL4 IL10
23 positive regulation of cellular respiration GO:1901857 9.52 IL4 IFNG
24 regulation of isotype switching GO:0045191 9.51 IL4 IL10
25 immune response GO:0006955 9.5 TNF IL4 IL10 IFNG FCGR3B FCGR3A
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IFNG
27 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 TNF LEP IL4 IFNG
28 receptor biosynthetic process GO:0032800 9.43 TNF IL10
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
30 positive regulation of nitrogen compound metabolic process GO:0051173 9.32 TNF IFNG
31 positive regulation of MHC class II biosynthetic process GO:0045348 8.8 IL4 IL10 IFNG

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 TNF IL4 IL10 IFNG CD40LG
2 virus receptor activity GO:0001618 9.33 SCARB2 PVR ICAM1
3 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....